Jessica E Haberer1, Elizabeth A Bukusi2, Nelly R Mugo3, Maria Pyra4, Catherine Kiptinness5, Kevin Oware6, Lindsey E Garrison7, Katherine K Thomas8, Nicholas Musinguzi9, Susan Morrison8, Peter L Anderson10, Kenneth Ngure11, Jared M Baeten12. 1. Center for Global Health, Massachusetts General Hospital, Boston, MA, USA; Department of Medicine, Harvard Medical School, Boston, MA, USA. Electronic address: jhaberer@mgh.harvard.edu. 2. Centre for Microbiology Research, Kenya Medical Research Institute, Kisumu, Kenya; Department of Global Health, University of Washington, Seattle, WA, USA. 3. Department of Global Health, University of Washington, Seattle, WA, USA; Center for Clinical Research, Kenya Medical Research Institute, Thika, Kenya. 4. Department of Medicine, University of Chicago, Chicago, IL, USA. 5. Center for Clinical Research, Kenya Medical Research Institute, Thika, Kenya. 6. Centre for Microbiology Research, Kenya Medical Research Institute, Kisumu, Kenya. 7. Center for Global Health, Massachusetts General Hospital, Boston, MA, USA. 8. Department of Global Health, University of Washington, Seattle, WA, USA. 9. Global Health Collaborative, Mbarara, Uganda. 10. Department of Pharmaceutical Sciences, University of Colorado, Denver, CO, USA. 11. Center for Clinical Research, Kenya Medical Research Institute, Thika, Kenya; Department of Community Heath, Jomo Kenyatta University of Agriculture and Technology, Nairobi, Kenya. 12. Department of Global Health, University of Washington, Seattle, WA, USA; Department of Medicine and Department of Epidemiology, University of Washington, Seattle, WA, USA; Gilead Sciences, Redwood City, CA, USA.
Abstract
BACKGROUND: Pre-exposure prophylaxis (PrEP) is highly effective for preventing HIV acquisition. However, adherence among young women (aged 18-24 years) has been challenging. SMS reminders have been shown to improve adherence to antiretroviral therapy in some contexts, including in combination with real-time adherence monitoring. We aimed to determine the effect of SMS reminders on PrEP adherence among young women in Kenya over a 2-year period. METHODS: The monitoring PrEP among young adult women (MPYA) study was an open label randomised controlled trial involving young adult women at high risk of HIV in Thika and Kisumu, Kenya. Participants were recruited from colleges, vocational institutions, informal settlements, and community-based organisations supporting young women. Women had to be aged 18-24 years and at high risk of HIV acquisition (defined as a VOICE risk score of 5 or higher, or being in a serodiscordant relationship). Study staff randomly assigned participants (1:1) to receive either SMS reminders (SMS reminder group) or no reminders (no SMS reminder group). Study group assignment was known to trial staff but masked to investigators. Reminders were initially sent daily and participants could switch to as-needed reminders (ie, sent only if they missed opening the monitor as expected) after 1 month. Study visits occurred at 1 month, 3 months, and then quarterly (ie, every 3 months). The primary outcome was PrEP adherence over 24 months measured with a real-time electronic monitor and assessed by negative binomial models adjusted for the study site and quarter among participants who collected PrEP. This trial is registered with ClinicalTrials.gov, NCT02915367. FINDINGS: Of 642 women initially approached, 348 eligible women were enrolled between Dec 21, 2016, and Feb 5, 2018. Participants were randomly assigned to either the SMS reminder group (n=173) or the no SMS reminder group (n=175). The median age was 21 years (IQR 19-22) and 228 (66%) of the 348 participants reported condomless sex in the month before baseline. 24 (14%) of the 173 participants assigned to receive daily SMS reminders later opted for as-needed reminders. 69 291 (97%) of 71 791 SMS reminders were sent as planned. Among participants collecting PrEP (thus potentially suggesting a desire for HIV protection), electronically monitored adherence averaged 26·8% over 24 months and was similar by study group (27·0% with SMS, 26·6% without SMS, adjusted incidence rate ratio 1·16 [95% CI 0·93-1·45], p=0·19). There were no serious adverse events related to trial participation; five social harms occurred in each study group, primarily related to PrEP use. INTERPRETATION: SMS reminders were ineffective in promoting PrEP adherence among young Kenyan women. Given the overall low adherence in the trial, additional interventions are needed to support PrEP use in this population. FUNDING: US National Institute of Mental Health.
BACKGROUND: Pre-exposure prophylaxis (PrEP) is highly effective for preventing HIV acquisition. However, adherence among young women (aged 18-24 years) has been challenging. SMS reminders have been shown to improve adherence to antiretroviral therapy in some contexts, including in combination with real-time adherence monitoring. We aimed to determine the effect of SMS reminders on PrEP adherence among young women in Kenya over a 2-year period. METHODS: The monitoring PrEP among young adult women (MPYA) study was an open label randomised controlled trial involving young adult women at high risk of HIV in Thika and Kisumu, Kenya. Participants were recruited from colleges, vocational institutions, informal settlements, and community-based organisations supporting young women. Women had to be aged 18-24 years and at high risk of HIV acquisition (defined as a VOICE risk score of 5 or higher, or being in a serodiscordant relationship). Study staff randomly assigned participants (1:1) to receive either SMS reminders (SMS reminder group) or no reminders (no SMS reminder group). Study group assignment was known to trial staff but masked to investigators. Reminders were initially sent daily and participants could switch to as-needed reminders (ie, sent only if they missed opening the monitor as expected) after 1 month. Study visits occurred at 1 month, 3 months, and then quarterly (ie, every 3 months). The primary outcome was PrEP adherence over 24 months measured with a real-time electronic monitor and assessed by negative binomial models adjusted for the study site and quarter among participants who collected PrEP. This trial is registered with ClinicalTrials.gov, NCT02915367. FINDINGS: Of 642 women initially approached, 348 eligible women were enrolled between Dec 21, 2016, and Feb 5, 2018. Participants were randomly assigned to either the SMS reminder group (n=173) or the no SMS reminder group (n=175). The median age was 21 years (IQR 19-22) and 228 (66%) of the 348 participants reported condomless sex in the month before baseline. 24 (14%) of the 173 participants assigned to receive daily SMS reminders later opted for as-needed reminders. 69 291 (97%) of 71 791 SMS reminders were sent as planned. Among participants collecting PrEP (thus potentially suggesting a desire for HIV protection), electronically monitored adherence averaged 26·8% over 24 months and was similar by study group (27·0% with SMS, 26·6% without SMS, adjusted incidence rate ratio 1·16 [95% CI 0·93-1·45], p=0·19). There were no serious adverse events related to trial participation; five social harms occurred in each study group, primarily related to PrEP use. INTERPRETATION: SMS reminders were ineffective in promoting PrEP adherence among young Kenyan women. Given the overall low adherence in the trial, additional interventions are needed to support PrEP use in this population. FUNDING: US National Institute of Mental Health.
Authors: Christina Psaros; Cecilia Milford; Jennifer A Smit; Letitia Greener; Nzwakie Mosery; Lynn T Matthews; Abigail Harrison; Janna R Gordon; Matthew Mimiaga; David R Bangsberg; Steven A Safren Journal: Arch Sex Behav Date: 2017-11-13
Authors: Jeanne M Marrazzo; Gita Ramjee; Barbra A Richardson; Kailazarid Gomez; Nyaradzo Mgodi; Gonasagrie Nair; Thesla Palanee; Clemensia Nakabiito; Ariane van der Straten; Lisa Noguchi; Craig W Hendrix; James Y Dai; Shayhana Ganesh; Baningi Mkhize; Marthinette Taljaard; Urvi M Parikh; Jeanna Piper; Benoît Mâsse; Cynthia Grossman; James Rooney; Jill L Schwartz; Heather Watts; Mark A Marzinke; Sharon L Hillier; Ian M McGowan; Z Mike Chirenje Journal: N Engl J Med Date: 2015-02-05 Impact factor: 91.245
Authors: Jia-Hua Zheng; Caitlin Rower; Kevin McAllister; Jose Castillo-Mancilla; Brandon Klein; Amie Meditz; L Anthony Guida; Jennifer J Kiser; Lane R Bushman; Peter L Anderson Journal: J Pharm Biomed Anal Date: 2016-01-21 Impact factor: 3.935
Authors: Jennifer E Balkus; Elizabeth Brown; Thesla Palanee; Gonasagrie Nair; Zakir Gafoor; Jingyang Zhang; Barbra A Richardson; Zvavahera M Chirenje; Jeanne M Marrazzo; Jared M Baeten Journal: J Acquir Immune Defic Syndr Date: 2016-07-01 Impact factor: 3.731
Authors: Jessica E Haberer; Angella Musiimenta; Esther C Atukunda; Nicholas Musinguzi; Monique A Wyatt; Norma C Ware; David R Bangsberg Journal: AIDS Date: 2016-05-15 Impact factor: 4.177
Authors: Ingrid T Katz; Kenneth Ngure; Kevin Kamolloh; Vallery Ogello; Moses Okombo; Nicholas B Thuo; Esther Owino; Lindsey E Garrison; Yeonsoo S Lee; Maria F Nardell; Chiemelie Anyacheblu; Elizabeth Bukusi; Nelly Mugo; Jared M Baeten; Jessica E Haberer Journal: AIDS Behav Date: 2022-08-05
Authors: Susan P Buchbinder; Aaron J Siegler; Kenneth Coleman; Eric Vittinghoff; Gretchen Wilde; Annie Lockard; Hyman Scott; Peter L Anderson; Nicole Laborde; Ariane van der Straten; Richard H Christie; Michelle Marlborough; Albert Y Liu Journal: AIDS Behav Date: 2022-08-19
Authors: Kenneth Ngure; Nelly R Mugo; Elizabeth A Bukusi; Catherine Kiptinness; Kevin Oware; Stephen Gakuo; Nicholas Musinguzi; Maria Pyra; Lindsey Garrison; Jared M Baeten; Jessica E Haberer Journal: J Acquir Immune Defic Syndr Date: 2021-12-01 Impact factor: 3.771
Authors: Jessica E Haberer; Nelly Mugo; Elizabeth Ann Bukusi; Kenneth Ngure; Catherine Kiptinness; Kevin Oware; Lindsey E Garrison; Nicholas Musinguzi; Maria Pyra; Susie Valenzuela; Katherine K Thomas; Peter L Anderson; Harsha Thirumurthy; Jared M Baeten Journal: J Acquir Immune Defic Syndr Date: 2022-03-01 Impact factor: 3.771
Authors: Andrew Mujugira; Agnes Nakyanzi; Maria S Nabaggala; Timothy R Muwonge; Timothy Ssebuliba; Monica Bagaya; Olivia Nampewo; Oliver Sapiri; Kikulwe R Nyanzi; Felix Bambia; Rogers Nsubuga; David M Serwadda; Norma C Ware; Jared M Baeten; Jessica E Haberer Journal: J Acquir Immune Defic Syndr Date: 2022-04-01 Impact factor: 3.771